Researchers conducted a phase 2, 52-week double-blind dose-ranging study of once-daily semaglutide versus a placebo, with liraglutide 3 mg serving as an active control. Each participant also received dietary and exercise counseling.
Approximately 83 percent of semaglutide patients lost greater than or equal to 5 percent of their body weight, with 65 percent losing greater than or equal to 10 percent of their body weight.
The most common adverse events were dose-related gastrointestinal events, which are present when GLP-1 receptor agonists are used.
Novo Nordisk Chief Science Officer Mads Krogsgaard Thomsen said the company will pursue a phase 3 clinical development program in late 2018.
More articles on anesthesia:
10 things to know about Surgical Care Affiliates
New York health system eliminating outpatient surgery due to freestanding surgery center proliferation — 5 insights
Working capital as a percentage of ASC net revenue by region — 14 statistics
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
